- Home
- CIIT vs LTRN Comparison
CIIT vs LTRN Comparison
Compare CIIT & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIIT
- LTRN
- Stock Information
- Founded
- CIIT N/A
- LTRN 2013
- Country
- CIIT Hong Kong
- LTRN United States
- Employees
- CIIT N/A
- LTRN N/A
- Industry
- CIIT
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- CIIT
- LTRN Health Care
- Exchange
- CIIT NYSE
- LTRN Nasdaq
- Market Cap
- CIIT 36.0M
- LTRN 36.0M
- IPO Year
- CIIT N/A
- LTRN 2020
- Fundamental
- Price
- CIIT $1.08
- LTRN $3.76
- Analyst Decision
- CIIT
- LTRN Strong Buy
- Analyst Count
- CIIT 0
- LTRN 1
- Target Price
- CIIT N/A
- LTRN $25.00
- AVG Volume (30 Days)
- CIIT 267.1K
- LTRN 333.1K
- Earning Date
- CIIT 06-09-2025
- LTRN 08-07-2025
- Dividend Yield
- CIIT N/A
- LTRN N/A
- EPS Growth
- CIIT N/A
- LTRN N/A
- EPS
- CIIT N/A
- LTRN N/A
- Revenue
- CIIT $9,464,501.00
- LTRN N/A
- Revenue This Year
- CIIT N/A
- LTRN N/A
- Revenue Next Year
- CIIT N/A
- LTRN N/A
- P/E Ratio
- CIIT N/A
- LTRN N/A
- Revenue Growth
- CIIT 51.52
- LTRN N/A
- 52 Week Low
- CIIT $0.56
- LTRN $2.55
- 52 Week High
- CIIT $5.38
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- CIIT N/A
- LTRN 54.71
- Support Level
- CIIT N/A
- LTRN $3.15
- Resistance Level
- CIIT N/A
- LTRN $4.43
- Average True Range (ATR)
- CIIT 0.00
- LTRN 0.41
- MACD
- CIIT 0.00
- LTRN 0.07
- Stochastic Oscillator
- CIIT 0.00
- LTRN 48.01
About CIIT TIANCI INTERNATIONAL INC
Tianci International Inc along with its subsidiaries is engaged in sale of components of electronic devices, development of software and websites, technical consulting, and providing maintenance support on customized software. The company's business is predominantly carried out in Hong Kong with a substantial portion of its overall revenue being generated from its Electronic Device Hardware Components Sales segment.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.